Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Visit the Session in upcoming 7th RAS-Targeted Drug Development Summit, Boston, Sept 16–18, 2025, Session: Sept.17, Thursday. Or, Call 978-269-4198 (m), Warren Park for in-person meetings! KN510713, ...

Two companion studies published in Cancer Research by scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C-mutant non-small ...

Antimicrobial resistance - when bacteria and fungi defend themselves against the drugs design to kill them - is an urgent threat to global public health, according to the Centers for Disease Control ...

In a recent paper published in Nature, researchers at the University of Chicago discovered how to block nicotinamide N-methyl transferase (NNMT), an enzyme that is involved in the progression of ...

In the decade since palbociclib (Ibrance) received FDA approval, results from multiple clinical trials have provided a strong evidence base to make cyclin-dependent kinase (CDK)4/6 inhibitors, in ...

Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and ...

DNMT1 inhibition as an approach to overcome sonic hedgehog-type medulloblastoma Aug. 29, 2024 ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine A study published in Nature suggests a variation in ...

(A, B) Western blotting analysis of FASN and PARP1 expression in stable MDA-MB-436 cells overexpressing FASN (MDA-MB-436/FASN) and MDA-MB-231 cells with FASN knockdown (MDA-MB-231/shFASN) along with ...

Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its ...